O	0	10	Prevention
O	11	13	of
B-condition	14	19	acute
I-condition	20	35	radiodermatitis
O	36	38	by
B-intervention	39	57	photobiomodulation
O	57	58	:
O	59	60	A
O	61	71	randomized
O	71	72	,
O	73	80	placebo
O	80	81	-
O	81	91	controlled
O	92	97	trial
O	98	100	in
O	101	107	breast
O	108	114	cancer
O	115	123	patients
O	124	125	(
O	125	136	TRANSDERMIS
O	137	142	trial
O	142	143	)
O	143	144	.

O	145	150	Acute
O	151	166	radiodermatitis
O	167	168	(
O	168	170	RD
O	170	171	)
O	172	174	is
O	175	176	a
O	177	188	distressing
O	189	192	and
O	193	200	painful
O	201	205	skin
O	206	214	reaction
O	215	219	that
O	220	226	occurs
O	227	229	in
O	230	232	95
O	232	233	%
O	234	236	of
O	237	240	the
O	241	249	patients
O	250	260	undergoing
O	261	273	radiotherapy
O	274	275	(
O	275	277	RT
O	277	278	)
O	278	279	.

O	280	283	The
O	284	287	aim
O	288	290	of
O	291	295	this
O	296	301	study
O	302	305	was
O	306	308	to
O	309	317	evaluate
O	318	321	the
O	322	335	effectiveness
O	336	338	of
O	339	357	photobiomodulation
O	358	365	therapy
O	366	367	(
O	367	371	PBMT
O	371	372	)
O	373	375	in
O	376	379	the
O	380	390	prevention
O	391	393	of
B-condition	394	399	acute
I-condition	400	402	RD
O	403	405	in
O	406	412	breast
O	413	419	cancer
O	420	421	(
O	421	423	BC
O	423	424	)
O	425	433	patients
O	434	444	undergoing
O	445	447	RT
O	447	448	.

O	449	453	This
O	454	459	study
O	460	463	was
O	464	465	a
O	466	476	randomized
O	476	477	,
O	478	485	placebo
O	485	486	-
O	486	496	controlled
O	497	502	trial
O	503	512	including
B-total-participants	513	516	120
B-eligibility	517	519	BC
I-eligibility	520	528	patients
I-eligibility	529	533	that
I-eligibility	534	543	underwent
I-eligibility	544	546	an
I-eligibility	547	556	identical
I-eligibility	557	559	RT
I-eligibility	560	567	regimen
I-eligibility	568	572	post
I-eligibility	572	573	-
I-eligibility	573	583	lumpectomy
O	583	584	.

O	585	593	Patients
O	594	598	were
O	599	607	randomly
O	608	616	assigned
O	617	619	to
O	620	623	the
O	624	629	laser
O	630	637	therapy
O	638	639	(
O	639	641	LT
O	641	642	)
O	643	645	or
B-control	646	653	placebo
O	654	659	group
O	659	660	,
O	661	665	with
B-intervention-participants	666	668	60
O	669	677	patients
O	678	680	in
O	681	685	each
O	686	691	group
O	691	692	.

O	693	698	Laser
O	699	701	or
O	702	709	placebo
O	710	720	treatments
O	721	725	were
O	726	733	applied
O	734	735	2
O	736	740	days
O	741	742	a
O	743	747	week
O	747	748	,
O	749	760	immediately
O	761	766	after
O	767	770	the
O	771	773	RT
O	774	781	session
O	781	782	,
O	783	791	starting
O	792	794	at
O	795	798	the
O	799	804	first
O	805	808	day
O	809	811	of
O	812	814	RT
O	814	815	.

O	816	820	PBMT
O	821	824	was
O	825	834	delivered
O	835	840	using
O	841	842	a
O	843	848	class
O	849	851	IV
O	852	855	MLS
O	855	856	®
O	857	859	M6
O	860	865	laser
O	866	870	that
O	871	879	combines
O	880	883	two
O	884	896	synchronized
O	897	902	laser
O	903	909	diodes
O	910	912	in
O	913	916	the
O	917	925	infrared
O	926	931	range
O	932	933	(
O	933	936	808
O	936	937	-
O	937	940	905
O	941	943	nm
O	943	944	)
O	945	949	with
O	950	951	a
O	952	957	fixed
O	958	964	energy
O	965	972	density
O	973	974	(
O	974	975	4
O	976	977	J
O	977	978	/
O	978	981	cm2
O	982	983	)
O	983	984	.

O	985	989	Skin
O	990	999	reactions
O	1000	1004	were
O	1005	1011	scored
O	1012	1017	based
O	1018	1020	on
O	1021	1024	the
O	1025	1033	criteria
O	1034	1036	of
O	1037	1040	the
O	1041	1050	Radiation
O	1051	1058	Therapy
O	1059	1067	Oncology
O	1068	1073	Group
O	1074	1075	(
O	1075	1079	RTOG
O	1079	1080	)
O	1081	1084	and
O	1085	1088	the
O	1089	1098	Radiation
O	1098	1099	-
O	1099	1106	Induced
O	1107	1111	Skin
O	1112	1120	Reaction
O	1121	1131	Assessment
O	1132	1137	Scale
O	1138	1139	(
O	1139	1145	RISRAS
O	1145	1146	)
O	1146	1147	.

O	1148	1151	The
O	1152	1160	patients
O	1161	1170	completed
O	1171	1174	the
O	1175	1182	Skindex
O	1182	1183	-
O	1183	1185	16
O	1186	1199	questionnaire
O	1200	1202	to
O	1203	1211	evaluate
O	1212	1217	their
O	1218	1225	quality
O	1226	1228	of
O	1229	1233	life
O	1233	1234	.

O	1235	1238	All
O	1239	1242	the
O	1243	1255	measurements
O	1256	1260	were
O	1261	1270	collected
O	1271	1273	at
O	1274	1277	the
O	1278	1283	first
O	1284	1287	day
O	1287	1288	,
O	1289	1291	at
O	1292	1293	a
O	1294	1296	RT
O	1297	1301	dose
O	1302	1304	of
O	1305	1307	40
O	1308	1312	Gray
O	1313	1314	(
O	1314	1316	Gy
O	1316	1317	)
O	1317	1318	,
O	1319	1322	and
O	1323	1325	at
O	1326	1329	the
O	1330	1333	end
O	1334	1336	of
O	1337	1339	RT
O	1340	1341	(
O	1341	1346	total
O	1347	1351	dose
O	1352	1354	66
O	1355	1357	Gy
O	1357	1358	)
O	1358	1359	.

O	1360	1362	At
O	1363	1364	a
O	1365	1367	RT
O	1368	1372	dose
O	1373	1375	of
O	1376	1378	40
O	1379	1381	Gy
O	1381	1382	,
O	1383	1388	there
O	1389	1392	was
O	1393	1395	no
O	1396	1407	significant
O	1408	1418	difference
O	1419	1426	between
O	1427	1430	the
O	1431	1437	groups
O	1438	1440	in
O	1441	1444	the
O	1445	1457	distribution
O	1458	1460	of
O	1461	1465	RTOG
O	1466	1472	grades
O	1472	1473	.

O	1474	1481	However
O	1481	1482	,
O	1483	1485	at
O	1486	1489	the
O	1490	1493	end
O	1494	1496	of
O	1497	1499	RT
O	1500	1503	the
O	1504	1512	severity
O	1513	1515	of
O	1516	1519	the
O	1520	1524	skin
O	1525	1534	reactions
O	1535	1548	significantly
O	1549	1557	differed
O	1558	1565	between
O	1566	1569	the
O	1570	1573	two
O	1574	1580	groups
O	1581	1582	(
O	1582	1583	P
O	1584	1585	=
O	1586	1587	0
O	1587	1588	.
O	1588	1591	004
O	1591	1592	)
O	1592	1593	,
O	1594	1598	with
O	1599	1600	a
O	1601	1607	larger
O	1608	1618	percentage
O	1619	1621	of
O	1622	1630	patients
O	1631	1643	experiencing
B-outcome	1644	1648	RTOG
I-outcome	1649	1654	grade
I-outcome	1655	1656	2
I-outcome	1657	1659	or
I-outcome	1660	1666	higher
O	1667	1668	(
O	1668	1669	e
O	1669	1670	.
O	1670	1671	g
O	1671	1672	.
O	1672	1673	,
O	1674	1679	moist
O	1680	1692	desquamation
O	1692	1693	)
O	1694	1696	in
O	1697	1700	the
O	1701	1708	placebo
O	1709	1714	group
O	1715	1716	(
B-cv-bin-percent	1716	1718	30
I-cv-bin-percent	1718	1719	%
O	1720	1722	vs
O	1722	1723	.
B-iv-bin-percent	1724	1725	6
I-iv-bin-percent	1725	1726	.
I-iv-bin-percent	1726	1727	7
I-iv-bin-percent	1727	1728	%
O	1728	1729	,
O	1730	1733	for
O	1734	1737	the
O	1738	1745	placebo
O	1746	1749	and
O	1750	1755	laser
O	1756	1761	group
O	1761	1762	,
O	1763	1767	resp
O	1767	1768	.
O	1768	1769	)
O	1769	1770	.

O	1771	1774	The
B-outcome	1775	1784	objective
I-outcome	1785	1791	RISRAS
I-outcome	1792	1797	score
O	1798	1807	confirmed
O	1808	1813	these
O	1814	1821	results
O	1821	1822	.

O	1823	1825	In
O	1826	1834	addition
O	1834	1835	,
O	1836	1839	the
O	1840	1847	Skindex
O	1847	1848	-
O	1848	1850	16
O	1851	1854	and
O	1855	1861	RISRAS
O	1862	1872	subjective
O	1873	1878	score
O	1879	1891	demonstrated
O	1892	1896	that
O	1897	1900	the
O	1901	1909	patients
O	1909	1910	'
B-outcome	1911	1918	quality
I-outcome	1919	1921	of
I-outcome	1922	1926	life
O	1927	1930	was
O	1931	1944	significantly
O	1945	1951	better
O	1952	1954	in
O	1955	1958	the
O	1959	1961	LT
O	1962	1966	than
O	1967	1969	in
O	1970	1973	the
O	1974	1981	control
O	1982	1987	group
O	1987	1988	.

O	1989	1992	The
O	1993	2000	results
O	2001	2003	of
O	2004	2008	this
O	2009	2014	trial
O	2015	2019	show
O	2020	2024	that
O	2025	2029	PBMT
O	2030	2032	is
O	2033	2035	an
O	2036	2045	effective
O	2046	2050	tool
O	2051	2053	to
O	2054	2061	prevent
O	2062	2065	the
O	2066	2077	development
O	2078	2080	of
B-outcome	2081	2086	grade
I-outcome	2087	2088	2
I-outcome	2089	2094	acute
I-outcome	2095	2097	RD
I-outcome	2098	2100	or
I-outcome	2101	2107	higher
O	2108	2110	in
O	2111	2113	BC
O	2114	2122	patients
O	2122	2123	.

O	2124	2126	In
O	2127	2135	addition
O	2135	2136	,
O	2137	2139	it
O	2140	2144	also
O	2145	2152	reduces
O	2153	2156	the
O	2157	2165	patients
O	2165	2166	'
O	2167	2175	symptoms
O	2176	2183	related
O	2184	2186	to
O	2187	2189	RD
O	2189	2190	.

O	2191	2197	Lasers
O	2198	2202	Surg
O	2202	2203	.
O	2203	2206	Med
O	2206	2207	.
O	2207	2208	©
O	2208	2212	2018
O	2213	2218	Wiley
O	2219	2230	Periodicals
O	2230	2231	,
O	2232	2235	Inc
O	2235	2236	.
